Study of oral therapy candidate indicates positive results for patients with mild-to-moderate COVID-19
Untangling COVID-19 and tuberculosis
25 March 2021COVID-19 vaccine hesitancy could lead to thousands of extra deaths
25 March 2021Study of oral therapy candidate indicates positive results for patients with mild-to-moderate COVID-19
New research by Kaleido Biosciences, Inc., and UMass Medical School investigators John P. Haran, MD, Ph.D., and Beth McCormick, Ph.D., shows that the company’s microbiome metabolic therapy candidate produced positive results in patients with mild-to-moderate COVID-19. The analysis showed a reduction in overall hospitalizations, emergency room visits and urgent care visits related to COVID-19.
